• Je něco špatně v tomto záznamu ?

Ectopic over-expression of miR-429 induces mesenchymal-to-epithelial transition (MET) and increased drug sensitivity in metastasizing ovarian cancer cells

L. Wang, R. Mezencev, M. Švajdler, BB. Benigno, JF. McDonald,

. 2014 ; 134 (1) : 96-103.

Jazyk angličtina Země Spojené státy americké

Typ dokumentu kazuistiky, časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc14074219

OBJECTIVE: We recently determined that the ectopic over-expression of miR-429 and other members of the miR-200 family of microRNAs in ovarian cancer (OC) mesenchymal-like cell lines induces mesenchymal-to-epithelial transition (MET) with a concomitant increase in sensitivity to platinum drugs. We sought to determine if metastasizing OC cells isolated from an OC patient could also be induced by miR-429 to undergo MET and become sensitized to established first-line platinum-based therapies. METHODS: We established and characterized a new primary cell line (OCI-984) from free-floating OC cells isolated from the ascites fluid of an advanced stage OC patient. miR-429 was ectopically over-expressed in these cells. RESULTS: The over-expression of miR-429 in OCI-984 cells induced morphological, functional and molecular changes consistent with MET and a concomitant significant increase in the sensitivity of the converted cells to cisplatin. CONCLUSIONS: Our findings indicate that the miR-200 family of microRNAs, and miR-429 in particular, play a critical role in the functioning of OC metastasizing cells and that targeted delivery of miR-429, and perhaps other miR-200 family members, in combination with platinum-based chemotherapies may be an effective strategy in reducing OC metastasis and tumor recurrence.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc14074219
003      
CZ-PrNML
005      
20141008095656.0
007      
ta
008      
141006s2014 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.ygyno.2014.04.055 $2 doi
035    __
$a (PubMed)24802724
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Wang, Lijuan $u Integrated Cancer Research Center, School of Biology and Parker H. Petit Institute of Bioengineering and Biosciences, Georgia Institute of Technology, 315 Ferst Drive, Atlanta GA 30332, USA. Electronic address: Lijuan.Wang@biology.gatech.edu.
245    10
$a Ectopic over-expression of miR-429 induces mesenchymal-to-epithelial transition (MET) and increased drug sensitivity in metastasizing ovarian cancer cells / $c L. Wang, R. Mezencev, M. Švajdler, BB. Benigno, JF. McDonald,
520    9_
$a OBJECTIVE: We recently determined that the ectopic over-expression of miR-429 and other members of the miR-200 family of microRNAs in ovarian cancer (OC) mesenchymal-like cell lines induces mesenchymal-to-epithelial transition (MET) with a concomitant increase in sensitivity to platinum drugs. We sought to determine if metastasizing OC cells isolated from an OC patient could also be induced by miR-429 to undergo MET and become sensitized to established first-line platinum-based therapies. METHODS: We established and characterized a new primary cell line (OCI-984) from free-floating OC cells isolated from the ascites fluid of an advanced stage OC patient. miR-429 was ectopically over-expressed in these cells. RESULTS: The over-expression of miR-429 in OCI-984 cells induced morphological, functional and molecular changes consistent with MET and a concomitant significant increase in the sensitivity of the converted cells to cisplatin. CONCLUSIONS: Our findings indicate that the miR-200 family of microRNAs, and miR-429 in particular, play a critical role in the functioning of OC metastasizing cells and that targeted delivery of miR-429, and perhaps other miR-200 family members, in combination with platinum-based chemotherapies may be an effective strategy in reducing OC metastasis and tumor recurrence.
650    _2
$a senioři $7 D000368
650    _2
$a zvířata $7 D000818
650    _2
$a protinádorové látky $x farmakologie $7 D000970
650    12
$a nádorové buněčné linie $7 D045744
650    _2
$a cisplatina $x farmakologie $7 D002945
650    _2
$a screeningové testy protinádorových léčiv $7 D004354
650    _2
$a epitelo-mezenchymální tranzice $x genetika $7 D058750
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a myši $7 D051379
650    _2
$a myši nahé $7 D008819
650    _2
$a mikro RNA $x biosyntéza $7 D035683
650    _2
$a nádory vaječníků $x farmakoterapie $x genetika $x patologie $7 D010051
650    _2
$a xenogenní modely - testy protinádorové aktivity $7 D023041
655    _2
$a kazuistiky $7 D002363
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Mezencev, Roman $u Integrated Cancer Research Center, School of Biology and Parker H. Petit Institute of Bioengineering and Biosciences, Georgia Institute of Technology, 315 Ferst Drive, Atlanta GA 30332, USA. Electronic address: rmezencev3@gatech.edu.
700    1_
$a Švajdler, Marián $u Bioptická Laboratoř, s.r.o., Pilsen, Czech Republic; Department of Pathology, Louis Pasteur University Hospital, Kosice, Slovakia. Electronic address: svajdler@yahoo.com.
700    1_
$a Benigno, Benedict B $u Ovarian Cancer Institute, 960 Johnson Ferry Road, Suite 130 Atlanta, GA 30342, USA. Electronic address: benedict.benigno@ugynonc.com.
700    1_
$a McDonald, John F $u Integrated Cancer Research Center, School of Biology and Parker H. Petit Institute of Bioengineering and Biosciences, Georgia Institute of Technology, 315 Ferst Drive, Atlanta GA 30332, USA; Ovarian Cancer Institute, 960 Johnson Ferry Road, Suite 130 Atlanta, GA 30342, USA. Electronic address: john.mcdonald@biology.gatech.edu.
773    0_
$w MED00001958 $t Gynecologic oncology $x 1095-6859 $g Roč. 134, č. 1 (2014), s. 96-103
856    41
$u https://pubmed.ncbi.nlm.nih.gov/24802724 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20141006 $b ABA008
991    __
$a 20141008100044 $b ABA008
999    __
$a ok $b bmc $g 1042102 $s 873131
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2014 $b 134 $c 1 $d 96-103 $i 1095-6859 $m Gynecologic oncology $n Gynecol Oncol $x MED00001958
LZP    __
$a Pubmed-20141006

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace

Nahrávání dat ...